Allergic Rhinitis
Conditions
Keywords
Allergic Rhinitis
Brief summary
The purpose of this study is to see how a combination spray of azelastine and fluticasone (antihistamine and steroid) compares with a steroid nasal spray (fluticasone) alone in allergic rhinitis i.e. does azelastine permit the use of lesser steroid dose (steroid sparing effect) to achieve the same benefit.
Detailed description
Allergic rhinitis (AR) is a major chronic respiratory disease with a prevalence approaching nearly 25% in the worldwide population.Allergic Rhinitis is a common and relatively undiagnosed public health problem and has been reported as being one of the ten most common causes for outpatient attendances to the general practitioner. Long term untreated allergic rhinitis may lead on to asthma. When exposed to allergens (pollen, house dust mite etc) in the atmosphere, the mast cells in the nose burst and an inflammatory response is triggered and patients experience sneezing, itching, blocked nose and running. These allergens may be used as provocation agents to recreate the disease symptoms to confirm the diagnosis of which allergens one is allergic to. However, there is a risk of allergic reactions in doing so. Adenosine monophosphate (AMP)achieves the same goal by stimulating the mast cells and causing them to burst without actually the risks of allergen provocation tests. Such tests are now commonplace in research and clinical medicine. Nasal steroids are considered to be the most potent medications for allergic rhinitis, particularly nasal blockage. Nasal antihistamines are also available but they act mainly to limit nasal running, itching and sneezing and have lesser effect on blockage. The other advantage is that they act very quickly while steroids take at least 72 hours to begin acting and weeks to achieve maximal benefit. Finally, they are free of significant short and long term side effects. Having said that nasal steroids are very safe and unlike inhaled or oral steroids have not been shown to cause systemic side effects in adults. Therefore, it is interesting to see if a combination of an antihistamine and nasal steroid would add their good qualities mentioned above and by the act of reducing the dose of steroid reduce their side effects. To do this we will use nasal AMP challenge as an outcome measure as we have done research studies for over a decade with. We will look at noninvasive nasal airflow parameters, nasal nitric oxide levels, and for safety we will look at the overnight urinary cortisol and creatinine ratio which is the most sensitive and noninvasive test of urine to quantify how much steroid has been absorbed in the blood stream.
Interventions
DRUGAzelastine , fluticasone
Azelastine Hydrochloride BP 0.10% w/v AND Fluticasone propionate BP 0.0357% w/v as combination 1 squirt in each nostril twice daily
DRUGFluticasone propionate
Fluticasone propionate 0.05% w/w 2 squirts in each nostril (50 μg per squirt)
Sponsors
University of Dundee
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Male of Female aged 18-65 years. * Persistent allergic rhinitis with or without asthma. * Atopy to at least one allergen on SPT. * Ability to give a written informed consent. * Ability and willingness to comply with the requirements of the protocol.
Exclusion criteria
* Recent respiratory tract/sinus infection within the last 2 months. . * Pregnancy, planned pregnancy or lactation. * Known or suspected hypersensitivity to any of the IMP's. * Concomitant use of medicines (prescribed, OTC or herbal) like alpha blockers that may interfere with the trial. * Nasal Polyposis grade 2+, Deviated nasal septum ≥ 50% * The use of oral corticosteroids within the last 3 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Maximum percentage fall in PNIF after 400mg/ml of AMP nasal challenge between both groups. | 0, 2 weeks, 4 weeks, 6 weeks, 8 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Mini RQLQ | 0, 2 weeks, 4 weeks, 6 weeks, 8 weeks |
| Global visual analogue scale | 0, 2 weeks, 4 weeks, 6 weeks, 8 weeks |
| 60 minute recovery to AMP challenge | 0, 2 weeks, 4 weeks, 6 weeks, 8 weeks |
| Overnight urinary cortisol creatinine ratio | 0, 2 weeks, 4 weeks, 6 weeks, 8 weeks |
| Domiciliary diary cards | 2 week treatment periods |
| Nasal lavage for cytokines | 0, 2 weeks, 4 weeks, 6 weeks, 8 weeks |
Countries
United Kingdom
Outcome results
None listed